New research from the Abramson Cancer Center at the University of Pennsylvania, published in the May 2019 issue of the Journal of the National Comprehensive Cancer Network uses a large, real-world dataset to demonstrate there is a modest but consistent survival benefit associated with adding bevacizumab to carboplatin-pemetrexed when treating advanced non-squamous non-small cell lung cancer.
“Backwater to Blockbuster,” the first de novo book published by the Cancer History Project, traces the evolution of St. Jude Children’s Research Hospital to its current status of a powerhouse of research in pediatric cancer.
